Astrana Health, Inc. (ASTH) Stock | ASTH Stock Price & Analysis

Feed

ASTH

Astrana Health, Inc. ASTH · NASDAQ

$37.45 -1.47% (-$0.56)

Summary

46 / 100 · Bulios Score

Valuation 62Growth 68Profitability 16Quality 32Debt 39Stability 70

What speaks for it

Revenue grew by 41% a year over the last 3 years.
The share price is below the Bulios Fair Price.
Analysts expect revenue to grow by 25% this fiscal year.

What to watch

Earnings per share fell by 23% a year over the last 3 years.
Out of every 100 USD of revenue, only 1.1 USD is left as net profit.
Operating profit covers the interest on its debt only 1.9 times.
It missed profit estimates 4 times in the last 8 quarters.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Is it expensive?

Looks cheap

Bulios Fair Price

Current price $37.45

P/E today 45.1 14% higher

5-year average P/E 39.5

P/E today 45.1

Medical - Care Facilities industry median

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 45.1 USD for 1 USD of yearly profit. Over the last five years it was 39.5 USD on average.

Valuation in detail

Is it growing?

Yes, fast

Revenue (USD)

774M

1.1B

1.4B

2.0B

3.2B

4.0B

4.4B

2021202220232024202520262027

Diluted EPS (USD)

$1.52

$0.99

$1.29

$0.90

$0.46

$1.41

$1.98

2021202220232024202520262027

Analyst estimate

Revenue grew by 54% a year over 5 years. Over the last 3 years it grew by 41% a year. For the next fiscal year analysts expect revenue to grow by 25%. Earnings per share fell by 23% a year over the last 3 years.

Growth in detail

Does it make money?

Poorly

Where 100 USD of revenue goes

Cost of sales 91 USD
Sales and administration 6.6 USD
Taxes and other 1.6 USD
Net profit 1.1 USD

Net profit, industry median (Medical - Care Facilities) 6.7 USD

Out of every 100 USD of revenue, 1.1 USD is left as net profit.

Profitability in detail

Is it financially healthy?

Debt is a burden

Cash and short-term investments $400.8M

Debt $979.4M

Free cash flow over 12 months $158.4M

Repaying all its debt would take 6.2 years of free cash flow. Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

Buy 11
Hold 0
Sell 0

Today's price within the analysts' price targets

Today's price $37.45 Average target $52

$37.45 $65

The average target of $52 is 39% above today's price. 100% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

Health Care Capitation Revenue 92%
Health Care, Patient Service 3.5%
Health Care, Other 2.7%
Management Service 1.0%
Product and Service, Other 0.9%

By region

The company reports no revenue by region.

Health Care Capitation Revenue brings in 92% of revenue.

Segments in detail